AMED stock icon

Amedisys

86.03 USD
+1.25
1.47%
At close Dec 6, 4:00 PM EST
After hours
84.90
-1.13
1.31%
1 day
1.47%
5 days
-5.77%
1 month
-11.95%
3 months
-11.46%
6 months
-5.93%
Year to date
-9.41%
1 year
-8.33%
5 years
-48.44%
10 years
228.74%
 

About: Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, high acuity care segment, and personal care services. The Home Health Segment provides skilled nurses, therapists, and aids to patients' homes throughout the United States, Hospice segment operates many centers designed to provide comfort and support for terminally ill patients, Personal Care Segment provides individuals with assistance in their daily living activities and High acuity care segment can deliver the essential elements of inpatient hospital, SNF care, and palliative care to patients in their homes. A majority of the company's revenue is derived from the Home Health segment.

Employees: 19,000

0
Funds holding %
of 6,794 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0% less capital invested

Capital invested by funds: $2.73B [Q2] → $2.72B (-$7.28M) [Q3]

3% less funds holding

Funds holding: 280 [Q2] → 272 (-8) [Q3]

4.77% less ownership

Funds ownership: 90.89% [Q2] → 86.12% (-4.77%) [Q3]

8% less funds holding in top 10

Funds holding in top 10: 12 [Q2] → 11 (-1) [Q3]

16% less first-time investments, than exits

New positions opened: 42 | Existing positions closed: 50

25% less repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 99

84% less call options, than puts

Call options by funds: $15.6M | Put options by funds: $97.6M

Research analyst outlook

We haven’t received any recent analyst ratings for AMED.

Financial journalist opinion

Based on 4 articles about AMED published over the past 30 days

Negative
Zacks Investment Research
3 weeks ago
DOJ Lawsuit Questions UnitedHealth's $3.3 Billion Amedisys Deal
The DOJ suggests that UNH's acquisitions reflect a strategy of buying competitors rather than competing directly, potentially giving it control over multiple markets.
DOJ Lawsuit Questions UnitedHealth's $3.3 Billion Amedisys Deal
Negative
Reuters
3 weeks ago
US sues to block UnitedHealth's $3.3 bln purchase of Amedisys
The Justice Department and three U.S. states filed a lawsuit on Tuesday to block UnitedHealth Group's $3.3 billion purchase of Amedisys Inc over concern the deal would harm competition in the market for home health services, the department said.
US sues to block UnitedHealth's $3.3 bln purchase of Amedisys
Negative
Reuters
3 weeks ago
US Justice Department preps suit over UnitedHealth-Amedisys deal, Bloomberg News reports
The U.S. Justice Department is moving to block UnitedHealth Group's $3.3 billion purchase of Amedisys Inc. over concerns the deal would harm competition in the market for home health services, Bloomberg News reported on Tuesday, citing people familiar with the matter.
US Justice Department preps suit over UnitedHealth-Amedisys deal, Bloomberg News reports
Negative
Zacks Investment Research
3 weeks ago
AMED Q3 Earnings and Revenues Miss, Margins Dip, Stock Falls
Amedisys, for the third quarter of 2024, delivers year-over-year top-line growth across three of its segments - Home Health, Hospice and High Acuity Care.
AMED Q3 Earnings and Revenues Miss, Margins Dip, Stock Falls
Positive
Zacks Investment Research
1 month ago
Amedisys (AMED) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Amedisys (AMED) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Amedisys (AMED) Reports Q3 Earnings: What Key Metrics Have to Say
Negative
Zacks Investment Research
1 month ago
Amedisys (AMED) Q3 Earnings and Revenues Lag Estimates
Amedisys (AMED) came out with quarterly earnings of $1 per share, missing the Zacks Consensus Estimate of $1.14 per share. This compares to earnings of $0.98 per share a year ago.
Amedisys (AMED) Q3 Earnings and Revenues Lag Estimates
Neutral
GlobeNewsWire
1 month ago
Amedisys Reports Third Quarter 2024 Financial Results
BATON ROUGE, La., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and nine-month periods ended September 30, 2024.
Amedisys Reports Third Quarter 2024 Financial Results
Positive
Zacks Investment Research
1 month ago
AMED or CHE: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Outpatient and Home Healthcare sector have probably already heard of Amedisys (AMED) and Chemed (CHE). But which of these two companies is the best option for those looking for undervalued stocks?
AMED or CHE: Which Is the Better Value Stock Right Now?
Positive
Zacks Investment Research
1 month ago
4 Stocks to Buy in an Evolving Outpatient Home Health Industry
Dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, EHC, AMED and ADUS are well-poised to gain.
4 Stocks to Buy in an Evolving Outpatient Home Health Industry
Positive
Zacks Investment Research
1 month ago
Will Amedisys (AMED) Beat Estimates Again in Its Next Earnings Report?
Amedisys (AMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Amedisys (AMED) Beat Estimates Again in Its Next Earnings Report?
Charts implemented using Lightweight Charts™